LT3204386T - Pakeistieji aminopurino junginiai, jų kompozicijos ir gydymo būdai jais - Google Patents
Pakeistieji aminopurino junginiai, jų kompozicijos ir gydymo būdai jaisInfo
- Publication number
- LT3204386T LT3204386T LTEP15848476.6T LT15848476T LT3204386T LT 3204386 T LT3204386 T LT 3204386T LT 15848476 T LT15848476 T LT 15848476T LT 3204386 T LT3204386 T LT 3204386T
- Authority
- LT
- Lithuania
- Prior art keywords
- aminopurin
- amended
- treatments
- compositions
- compounds
- Prior art date
Links
- MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical class NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462060339P | 2014-10-06 | 2014-10-06 | |
| PCT/US2015/053941 WO2016057370A1 (en) | 2014-10-06 | 2015-10-05 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3204386T true LT3204386T (lt) | 2021-07-12 |
Family
ID=55632334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP15848476.6T LT3204386T (lt) | 2014-10-06 | 2015-10-05 | Pakeistieji aminopurino junginiai, jų kompozicijos ir gydymo būdai jais |
Country Status (28)
| Country | Link |
|---|---|
| US (8) | US9512124B2 (lt) |
| EP (2) | EP3204386B1 (lt) |
| JP (4) | JP6884701B2 (lt) |
| KR (2) | KR20230035424A (lt) |
| CN (2) | CN113248506A (lt) |
| AR (2) | AR102171A1 (lt) |
| AU (2) | AU2015328414B2 (lt) |
| CA (1) | CA2963639C (lt) |
| CL (1) | CL2017000820A1 (lt) |
| CO (1) | CO2017003838A2 (lt) |
| CY (1) | CY1124173T1 (lt) |
| DK (1) | DK3204386T3 (lt) |
| EA (1) | EA201790779A1 (lt) |
| EC (1) | ECSP17026210A (lt) |
| ES (2) | ES2871142T3 (lt) |
| HR (1) | HRP20210656T1 (lt) |
| HU (1) | HUE054694T2 (lt) |
| IL (2) | IL251566B (lt) |
| LT (1) | LT3204386T (lt) |
| MX (2) | MX388321B (lt) |
| PL (1) | PL3204386T3 (lt) |
| PT (1) | PT3204386T (lt) |
| RS (1) | RS61884B1 (lt) |
| SG (2) | SG11201702759XA (lt) |
| SI (1) | SI3204386T1 (lt) |
| SM (1) | SMT202100302T1 (lt) |
| TW (1) | TW201629063A (lt) |
| WO (1) | WO2016057370A1 (lt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230035424A (ko) * | 2014-10-06 | 2023-03-13 | 시그날 파마소티칼 엘엘씨 | 치환된 아미노퓨린 화합물, 그의 조성물 및 그를 사용한 치료 방법 |
| EP3233808B1 (en) | 2014-12-16 | 2021-07-14 | Signal Pharmaceuticals, LLC | Medical uses comprising methods for measurement of inhibition of c-jun n-terminal kinase in skin |
| EP3250557B1 (en) | 2015-01-29 | 2024-11-20 | Signal Pharmaceuticals, LLC | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
| SG11201707473VA (en) | 2015-03-18 | 2017-10-30 | Bristol Myers Squibb Co | Heterocyclic compounds useful as inhibitors of tnf |
| SG11201707471RA (en) | 2015-03-18 | 2017-10-30 | Bristol Myers Squibb Co | Tricyclic heterocyclic compounds useful as inhibitors of tnf |
| BR112017019773A2 (pt) | 2015-03-18 | 2018-05-15 | Bristol-Myers Squibb Company | compostos heterocíclicos tricíclicos substituídos |
| ES2819374T3 (es) | 2015-07-24 | 2021-04-15 | Celgene Corp | Métodos de síntesis del hidrocloruro de (1R,2R,5R)-5-amino-2-metilciclohexanol e intermedios útiles en los mismos |
| JP6811233B2 (ja) | 2015-08-03 | 2021-01-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｔｎｆアルファの修飾因子として有用な環状化合物 |
| SG11201808388QA (en) * | 2016-04-01 | 2018-10-30 | Signal Pharm Llc | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
| SI3436019T1 (sl) * | 2016-04-01 | 2021-12-31 | Signal Pharmaceuticals, Llc | (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahidro-2h-piran-4-il)amino)-8-((2,4, 6-triklorofenil)amino)-9h-purin-9-il)-1-metilcikloheksane-1-karboksamid in metode uporabe |
| ES2926149T3 (es) * | 2016-06-02 | 2022-10-24 | Celgene Corp | Agentes antipalúdicos animales y humanos |
| US10010555B2 (en) | 2016-06-02 | 2018-07-03 | Celgene Corporation | Animal and human anti-trypanosomonal and anti-leishmania agents |
| EP3692041A1 (en) * | 2017-10-04 | 2020-08-12 | Celgene Corporation | Processes for the preparation of cis-4 [2-{(3s.4r)-3-fluorooxan-4-yl]amino)-8-(2,4,6-trichloroanilino)-9h-purin-9-yl]-1-methylcyclohexane-1-carboxamide |
| EP3691687A1 (en) * | 2017-10-04 | 2020-08-12 | Celgene Corporation | Compositions and methods of use of cis-4-[2-{[(3s,4r)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9h-purin-9-yl]-1-methylcyclohexane-1-carboxamide |
| CN115916747A (zh) * | 2020-07-01 | 2023-04-04 | 四川海思科制药有限公司 | 一种并环杂环衍生物及其在医药上的应用 |
| WO2023107705A1 (en) | 2021-12-10 | 2023-06-15 | Incyte Corporation | Bicyclic amines as cdk12 inhibitors |
| CN114478326B (zh) * | 2022-01-21 | 2023-10-03 | 安徽宁亿泰科技有限公司 | 一种苯嘧磺草胺关键中间体的合成方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL99699A (en) | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
| FI109088B (fi) | 1997-09-19 | 2002-05-31 | Leiras Oy | Tabletti ja menetelmä sen valmistamiseksi |
| CZ27399A3 (cs) * | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
| US7672705B2 (en) * | 2004-07-19 | 2010-03-02 | Resonant Medical, Inc. | Weighted surface-to-surface mapping |
| US7521446B2 (en) | 2005-01-13 | 2009-04-21 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| US7759342B2 (en) | 2005-01-13 | 2010-07-20 | Signal Pharmaceuticals, Llc | Methods of treatment and prevention using haloaryl substituted aminopurines |
| US7723340B2 (en) | 2005-01-13 | 2010-05-25 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| CN101360725B (zh) | 2005-11-18 | 2011-09-21 | 阿斯利康公司 | 固体制剂 |
| JO3235B1 (ar) | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
| NZ576347A (en) | 2006-10-27 | 2011-10-28 | Signal Pharm Llc | Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and use therewith |
| DK2279731T3 (da) | 2008-04-23 | 2013-03-18 | Farmasierra Mfg S L | Forbedret farmaceutisk sammensætning, som indeholder ibuprofen og codein |
| US20130034495A1 (en) | 2009-12-09 | 2013-02-07 | Marie Georges Beauchamps | Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol |
| US8680076B2 (en) | 2010-10-25 | 2014-03-25 | Signal Pharmaceuticals, Llc | Methods of treatment, improvement and prevention using haloaryl substituted aminopurines |
| US8603527B2 (en) | 2010-10-25 | 2013-12-10 | Signal Pharmaceuticals, Llc | Pharmaceutical formulations of a substituted diaminopurine |
| US20160082015A1 (en) | 2013-04-18 | 2016-03-24 | President And Fellows Of Harvard College | Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders |
| GB201321737D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| KR20230035424A (ko) * | 2014-10-06 | 2023-03-13 | 시그날 파마소티칼 엘엘씨 | 치환된 아미노퓨린 화합물, 그의 조성물 및 그를 사용한 치료 방법 |
| SI3436019T1 (sl) | 2016-04-01 | 2021-12-31 | Signal Pharmaceuticals, Llc | (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahidro-2h-piran-4-il)amino)-8-((2,4, 6-triklorofenil)amino)-9h-purin-9-il)-1-metilcikloheksane-1-karboksamid in metode uporabe |
-
2015
- 2015-10-05 KR KR1020237006598A patent/KR20230035424A/ko not_active Withdrawn
- 2015-10-05 EP EP15848476.6A patent/EP3204386B1/en active Active
- 2015-10-05 JP JP2017538172A patent/JP6884701B2/ja active Active
- 2015-10-05 CN CN202110381676.XA patent/CN113248506A/zh active Pending
- 2015-10-05 WO PCT/US2015/053941 patent/WO2016057370A1/en not_active Ceased
- 2015-10-05 EP EP20214685.8A patent/EP3822274B1/en active Active
- 2015-10-05 AU AU2015328414A patent/AU2015328414B2/en active Active
- 2015-10-05 AR ARP150103202A patent/AR102171A1/es not_active Application Discontinuation
- 2015-10-05 SM SM20210302T patent/SMT202100302T1/it unknown
- 2015-10-05 US US14/874,513 patent/US9512124B2/en active Active
- 2015-10-05 RS RS20210632A patent/RS61884B1/sr unknown
- 2015-10-05 KR KR1020177010551A patent/KR102504849B1/ko active Active
- 2015-10-05 SG SG11201702759XA patent/SG11201702759XA/en unknown
- 2015-10-05 LT LTEP15848476.6T patent/LT3204386T/lt unknown
- 2015-10-05 ES ES15848476T patent/ES2871142T3/es active Active
- 2015-10-05 EA EA201790779A patent/EA201790779A1/ru unknown
- 2015-10-05 ES ES20214685T patent/ES2980464T3/es active Active
- 2015-10-05 PT PT158484766T patent/PT3204386T/pt unknown
- 2015-10-05 CA CA2963639A patent/CA2963639C/en active Active
- 2015-10-05 DK DK15848476.6T patent/DK3204386T3/da active
- 2015-10-05 HU HUE15848476A patent/HUE054694T2/hu unknown
- 2015-10-05 SI SI201531584T patent/SI3204386T1/sl unknown
- 2015-10-05 TW TW104132732A patent/TW201629063A/zh unknown
- 2015-10-05 PL PL15848476T patent/PL3204386T3/pl unknown
- 2015-10-05 MX MX2017004600A patent/MX388321B/es unknown
- 2015-10-05 SG SG10202009598VA patent/SG10202009598VA/en unknown
- 2015-10-05 CN CN201580065272.2A patent/CN107001372B/zh active Active
- 2015-10-05 HR HRP20210656TT patent/HRP20210656T1/hr unknown
-
2016
- 2016-10-27 US US15/335,619 patent/US9737541B2/en active Active
-
2017
- 2017-04-04 CL CL2017000820A patent/CL2017000820A1/es unknown
- 2017-04-04 IL IL251566A patent/IL251566B/en active IP Right Grant
- 2017-04-06 MX MX2021014531A patent/MX2021014531A/es unknown
- 2017-04-20 CO CONC2017/0003838A patent/CO2017003838A2/es unknown
- 2017-04-27 EC ECIEPI201726210A patent/ECSP17026210A/es unknown
- 2017-07-05 US US15/641,383 patent/US10149849B2/en active Active
-
2018
- 2018-10-24 US US16/169,414 patent/US10398700B2/en active Active
-
2019
- 2019-07-17 US US16/514,749 patent/US10646493B2/en active Active
- 2019-10-02 JP JP2019182133A patent/JP6987823B2/ja active Active
-
2020
- 2020-02-28 AU AU2020201486A patent/AU2020201486B2/en active Active
- 2020-04-13 US US16/846,503 patent/US10940152B2/en active Active
- 2020-09-01 IL IL277069A patent/IL277069B/en unknown
-
2021
- 2021-01-12 US US17/147,127 patent/US11590139B2/en active Active
- 2021-05-24 CY CY20211100444T patent/CY1124173T1/el unknown
- 2021-12-01 JP JP2021195105A patent/JP7196270B2/ja active Active
-
2022
- 2022-12-14 JP JP2022199122A patent/JP2023027269A/ja active Pending
-
2023
- 2023-01-11 US US18/095,670 patent/US20230158035A1/en not_active Abandoned
- 2023-03-09 AR ARP230100589A patent/AR128748A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3204386T (lt) | Pakeistieji aminopurino junginiai, jų kompozicijos ir gydymo būdai jais | |
| LT3317284T (lt) | Benzoksazepino oksazolidinono junginiai ir jų naudojimo būdai | |
| LT3221306T (lt) | Heteroarilo junginiai, kaip irak inhibitoriai ir jų panaudojimas | |
| LT3206497T (lt) | Kompozicijos ir būdai, skirti meibomo liaukos disfunkcijos gydymui | |
| LT3230281T (lt) | 1,3-tiazol-2-ilu pakeisti benzamidai | |
| DE112015005065A5 (de) | Handschuh | |
| FI20165606A7 (fi) | Lämpökäsittely | |
| LT3240895T (lt) | Kompozicijos ir būdai, skirti baltymų glikozilinimui | |
| DK3139769T3 (da) | Næringsrige sammensætninger | |
| LT3102555T (lt) | Junginių kompozicijos ir jų panaudojimas | |
| EP3236978C0 (en) | An antimicrobial composition | |
| DK3231444T3 (da) | Ny behandling | |
| LT3200815T (lt) | Būdai ir kompozicijos, skirti vėžio gydymui | |
| LT3399978T (lt) | Antiproliferaciniai junginiai, jų farmacinės kompozicijos ir naudojimas | |
| DK3344664T3 (da) | Biocide blandinger | |
| HRP20200171T1 (hr) | Modificiranje bakteriofaga | |
| EP3493821A4 (en) | METHOD OF TREATING THE RESPIRATORY TRACT | |
| LT3321020T (lt) | Sudurtinai sutvirtintų ruošinių, tiksliau - juostinių pjūklų ir juostinių peilių, vėlesnio apdirbimo įrenginys | |
| FR3020948B1 (fr) | Composition antimicrobienne | |
| DK3129721T3 (da) | Kemisk spjæld | |
| FR3025106B1 (fr) | Composition antimicrobienne | |
| DK3233104T3 (da) | Immunterapi-behandlinger og -sammensætninger | |
| MA40840A (fr) | Composition herbicide | |
| FI20165552A7 (fi) | Otsonaattori | |
| DE112015004174A5 (de) | Organisches Bauelement |